Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

Pharmaceutical Investing

Agile Therapeutics (Nasdaq:AGRX), a women’s healthcare company, today reported financial results for the three months and year ended December 31, 2017 and provided a corporate update. As quoted in the press release: “We are focused on preparing for our upcoming meeting with the FDA to discuss the points identified in the CRL and a potential …

Agile Therapeutics (Nasdaq:AGRX), a women’s healthcare company, today reported financial results for the three months and year ended December 31, 2017 and provided a corporate update.

As quoted in the press release:

“We are focused on preparing for our upcoming meeting with the FDA to discuss the points identified in the CRL and a potential path forward for the approval of Twirla,” stated Al Altomari, Chairman and Chief Executive Officer of Agile. “We believe that Twirla, if approved, will provide women with a new contraceptive option in the form of a patch that is designed to deliver a low dose of estrogen and offer greater convenience for women.”

Click here to read the full press release.

approval corporate update fda financial results therapeutics women Pharmaceutical Investing